Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q3Scopus Q2
- 저널
- INTERNATIONAL JOURNAL OF HEMATOLOGY113(1) · pp.81 · 2021
- 피인용
- Web of Science 5Scopus 5
- FWCI (Scopus)
- 0.17
- JCR IF
- JCR 2020 2.49
- ISSN
- 0925-5710
저자
- Lee, Ho Sup제1저자Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea
- Kim, KihyunDepartment of Medicine, Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, South Korea
- Lee, Je-JungDepartment of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Jeollanamdo, South Korea
- Yoon, Sung-SooDepartment of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
- Bang, Soo-MeeDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea
- Kim, Jin SeokDivision of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea
- Eom, Hyeon-SeokDepartment of Internal Medicine, National Cancer Center of Korea, Goyang, South Korea
- Yoon, Dok HyunDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
- Lee, YoojinDepartment of Hematology/Oncology, Kyungpook National University Hospital, Daegu, South Korea
- 신호진Department of Internal Medicine, Pusan National University Hospital, Busan, South Korea
- Park, YongDepartment of Internal Medicine, Korea University College of Medicine, Seoul, South Korea
- Jo, Jae-CheolDepartment of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea
- Lee, Won SikDepartment of Internal Medicine, Busan Paik Hospital, Busan, South Korea
- Do, Young RokDepartment of Hemato-Oncology, Keimyung University Dongsan Medical Center, Daegu, South Korea
- Mun, Yeung-ChulDepartment of Internal Medicine, Ewha Womans University School of Medicine, Seoul, South Korea
- Lee, Mark HongDivision of Hematology-Oncology, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, South Korea
- Kim, Hyo JungDepartment of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, South Korea
- Kim, Sung-HyunDepartment of Internal Medicine, Dong-A Medical Center, Dong-A University College of Medicine, Busan, South Korea
- Kim, Min KyoungDepartment of Medicine, Yeungnam University College of Medicine, Daegu, South Korea
- Lim, Sung-NamDepartment of Internal Medicine, Haeundae Baek Hospital, Busan, South Korea
- Park, Seong KyuDepartment of Hematology/Oncology, Soonchunhyang University Bucheon Hospital, Bucheon, South Korea
- Yi, Jun HoDivision of Hematology-Oncology, Department of Medicine, Chung-Ang University, Seoul, South Korea
- Lee, Jae HoonDepartment of Internal Medicine, Gachon University Gil Hospital, Incheon, South Korea
- Min, Chang-Ki교신저자Department of Internal Medicine, Seoul St. Mary’s Hospital, Catholic University of Korea, 505, Banpo-dong, Seocho-gu, Seoul, 137-701, South Korea
초록
We compared efficacy and safety, according to frailty, of elderly patients with relapsed and refractory multiple myeloma (RRMM) treated with lenalidomide and dexamethasone (Rd), for whom bortezomib treatment had failed. Patients, 164 (52.9%) and 146 (47.1%), were classified as non-frail and frail using a simplified frailty scale. The overall response rates (ORR) and survival outcomes were lower in frail than in non-frail patients (ORR: 56.2% vs. 67.7%,P = 0.069; median progression free survival: 13.17 vs. 17.80 months,P = 0.033; median overall survival: 23.00 vs. 36.27 months,P = 0.002, respectively). The number of treatment emergent adverse events in grade 3 or worse was higher in frail than in non-frail patients (41.8% vs. 24.4%,P = 0.002, respectively). In frail patients, independent poor prognostic factors for survival were two or more Charlson comorbidity index (CCI) score, prior to exposure to both bortezomib and thalidomide, and achieved less than partial response In conclusion, frailty could predict clinical outcomes of Rd treatment in elderly patients with RRMM who had failed prior bortezomib. In frail patients, lower CCI in addition to less previous treatment exposure and deep response were associated with better survival.
키워드
Elderly multiple myelomaRelapsed and refractoryLenalidomide and dexamethasoneFrailtySurvivalGERIATRIC ASSESSMENTCONSENSUSSURVIVALTHERAPY
식별자
- Scopus EID
- 2-s2.0-85090196162
- WoS UID
- 000566332800002



로그인
연구물 목록으로